Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 2
---
 their intrinsic value due to factors we believe are temporary — We are disciplined and patient in our capital allocation, holding our investments for years, and sometimes decades ▪ We pride ourselves on building and maintaining constructive relationships with the companies in which we invest — We partner with companies throughout their lifecycle, providing capital, guidance and access to our network and expertise, with the ability to add additional value through board positions when appropriate ▪ We have been a committed investor in, and strong supporter of, STAAR Surgical Company (“STAAR” or the “Company”) for more than 30 years — From time to time, we have supported, STAAR, its Board of Directors (the “Board”) and its management team by providing direct financing and identifying and recommending new directors — We have added to our position over time because we believe STAAR’s EVO Implantable Collamer® Lens technology is ideally positioned to emerge as the superior choice for surgeons and patients in the global and refractive surgery market — Today, we beneficially own approximately 27.5% of STAAR’s outstanding shares, making us the Company’s largest stockholder by a significant margin — We do not have – and have never had – any interest in controlling STAAR; we are opposing the Proposed Merger because we believe strongly in STAAR’s ability to independently deliver value to stockholders that, on a risk - adjusted basis, is far in excess of the $28 per share that Alcon is offering

Broadwood Partners, L.P. Overview of STAAR Surgical (NASDAQ: STAA) 5 1. Source: STAAR Annual Reports on Form 10 - K for the applicable fiscal year. 2. Source: Wells Fargo Research Note, April 21, 2025. 3. Source: Goldman Sachs Aier Financial Model, August 27, 2025. 4. Source: FactSet. 5. As of September 23, 2025. 6. As of December 27, 2024. 7. Source: STAAR Investor Presentation, September 14, 2023. STAAR Surgical is a leading developer, manufacturer and marketer of implantable lenses for refractive vision correction $1,131 Enterprise Value ($M) 5 $1,316 Market Value ($M) 5 $0 Total Debt ($M) 5 $185 Cash and Equivalents ($M) 5 $224 LTM Net Sales ($M) 5 ($46) LTM Adjusted EBITDA ($M